Physician profile
Modupe E James
NPI 1801332853
$2,446.30
in general payments reported to CMS, 2019-2025
16 companies · $917 in 2025
The $917 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.86 · 2022: $196 · 2023: $733 · 2024: $526 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.28 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $321.76 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $291.06 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $285.94 | 2024-2025 | Cobenfy |
| Corium, LLC | $282.05 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.12 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $185.16 | 2022-2024 | Jornay Pm |
| Abbvie INC. | $156.97 | 2023 | |
| Indivior INC. | $152.79 | 2022-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $144.80 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $135.63 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $126.99 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $70.47 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $43.69 | 2024 | Qelbree |
| Tris Pharma INC | $19.29 | 2024 | Dyanavel Xr |
| Luye Pharma (USA) Ltd. | $14.78 | 2025 | Erzofri Extended-Release |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $13.80 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Modupe James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.